We are live on ! Find out more
GPCM

Granite Point Capital Management Portfolio holdings

AUM $4.9M
1-Year Est. Return 38.41%
This Fund
S&P 500
This Quarter Est. Return
+20.77%
1 Year Est. Return
+38.41%
3 Year Est. Return
+124.67%
5 Year Est. Return
+295.96%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
+$547M
Cap. Flow
+$491M
Cap. Flow %
48%
Top 10 Hldgs %
88.16%
Holding
123
New
24
Increased
19
Reduced
32
Closed
28

Top Buys

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$4.7M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.17M
3
WNC icon
Wabash National
WNC
+$1.87M
4
SAGE
Sage Therapeutics
SAGE
+$1.75M
5
PRTA icon
Prothena Corp
PRTA
+$1.53M

Top Sells

Rank Stock Value
1
HIMX
Himax Technologies
HIMX
+$4.17M
2
MB
MINDBODY, Inc. Class A Common Stock
MB
+$2.9M
3
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$2.74M
4
AMD icon
Advanced Micro Devices
AMD
+$2.52M
5
MYND
Mynd.ai
MYND
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 5.08%
2 Technology 2.88%
3 Communication Services 2.01%
4 Consumer Discretionary 1.64%
5 Industrials 1.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
CALL
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$470M 45.97%
+1,760,000
New +$458M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$453B
$322M 31.54%
2,069,000
+604,500
+41% +$92.3M
AAPL icon
3
CALL
Apple
AAPL
$4.54T
$42.3M 4.14%
1,000,000
+200,000
+25% +$8.36M
MRNS
4
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$18.6M 1.82%
569,712
-101,500
-15% -$2.74M
HIMX
5
Himax Technologies
HIMX
$2.19B
$9.4M 0.92%
902,100
-384,500
-30% -$4.17M
ADMS
6
DELISTED
Adamas Pharmaceuticals
ADMS
$9.17M 0.9%
270,515
-63,000
-19% -$1.76M
META icon
7
Meta Platforms (Facebook)
META
$1.42T
$8.97M 0.88%
50,850
-7,600
-13% -$1.34M
AXGN icon
8
Axogen
AXGN
$2.27B
$7.75M 0.76%
273,751
– –
GOOS
9
Canada Goose Holdings
GOOS
$872M
$6.82M 0.67%
216,200
+41,200
+24% +$1.01M
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$5.87M 0.57%
146,500
+82,400
+129% +$3.17M
GWPH
11
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.28M 0.52%
+40,000
New +$4.7M
NTES icon
12
NetEase
NTES
$85.3B
$5M 0.49%
72,500
+23,500
+48% +$1.47M
GLNG icon
13
Golar LNG
GLNG
$5B
$4.47M 0.44%
150,000
+5,000
+3% +$120K
SBBP
14
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.12M 0.4%
567,895
– –
NVDA icon
15
NVIDIA
NVDA
$4.86T
$3.23M 0.32%
668,000
-12,000
-2% -$59.6K
GOOGL icon
16
Alphabet (Google) Class A
GOOGL
$4.36T
$3.16M 0.31%
60,000
+26,000
+76% +$1.34M
SAGE
17
DELISTED
Sage Therapeutics
SAGE
$2.96M 0.29%
+18,000
New +$1.75M
LITE icon
18
Lumentum
LITE
$55.5B
$2.84M 0.28%
58,000
-39,300
-40% -$2.19M
AERI
19
DELISTED
Aerie Pharmaceuticals
AERI
$2.75M 0.27%
46,000
-3,800
-8% -$230K
SMMT icon
20
Summit Therapeutics
SMMT
$10.4B
$2.68M 0.26%
242,113
– –
NPTN
21
DELISTED
NEOPHOTONICS CORP
NPTN
$2.55M 0.25%
388,000
-70,302
-15% -$429K
CEVA icon
22
CEVA Inc
CEVA
$910M
$2.5M 0.24%
54,139
+29,139
+117% +$1.34M
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.57B
$2.46M 0.24%
44,220
-2,300
-5% -$122K
ZAGG
24
DELISTED
ZAGG Inc Common Stock (Delaware)
ZAGG
$2.44M 0.24%
132,200
+23,700
+22% +$443K
JPM icon
25
JPMorgan Chase
JPM
$935B
$2.28M 0.22%
21,300
-2,200
-9% -$223K
1
2 3 4 5

Similar funds

MAM
Moelis Asset Management New York $5.32M AUM
CCM
Compton Capital Management Providence, Rhode Island $4.32M AUM 27.38% 1-Year Est. Return
BGCI
Bertram Growth Capital III Foster City, California $6.05M AUM 39.41% 1-Year Est. Return
CAM
Chatham Asset Management Chatham, New Jersey $376K AUM
EAM
Emso Asset Management London, United Kingdom $255K AUM 6.95% 1-Year Est. Return
SM
SG3 Management Dorado, Puerto Rico $6.45K AUM 61.81% 1-Year Est. Return
TPL
Tao Pro LLC San Francisco, California $13.8M AUM 74.14% 1-Year Est. Return
RC
Resonate Capital San Francisco, California $15.4M AUM 24.26% 1-Year Est. Return

Granite Point Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Granite Point Capital Management held 123 positions worth $1.02B, up 115% from $475M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Granite Point Capital Management deployed $491M of net new capital in Q4 2017, opening 24 new positions and adding to 19 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 40,000 shares worth $5.28M.

By sector, the portfolio is most concentrated in Healthcare at 5.1% of assets, down from 8.5% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Himax Technologies, an estimated $4.17M trimmed.

  • Granite Point Capital Management's largest Q4 2017 buy was GW Pharmaceuticals Plc American Depositary Shares: 40,000 shares worth $5.28M.
  • Granite Point Capital Management added most to Zogenix, Inc. in Q4 2017, an estimated $3.17M increase.
  • Granite Point Capital Management's biggest Q4 2017 reduction was Himax Technologies, cutting an estimated $4.17M.
  • Granite Point Capital Management fully exited MINDBODY, Inc. Class A Common Stock in Q4 2017, selling an estimated $2.9M.
  • Granite Point Capital Management's ten largest holdings make up 88% of its $1.02B portfolio in Q4 2017.
  • Granite Point Capital Management opened 24 new positions and closed 28 in Q4 2017.
  • Granite Point Capital Management's portfolio value rose 115% quarter-over-quarter to $1.02B.

Based on Granite Point Capital Management's 13F filing for Q4 2017, filed 8 Feb 2018.